2023 Springer Nature Switzerland AG. Oddzial w Poznaniu, Warszawa, Woj Mazowieckie, Poland, 04-730, Szpital Uniwersytecki Nr 2 im. Article PanAmerican Clinical Research Mexico S.A. de C.V. Santiago de Queretaro, Queretaro, Mexico, 76226, Instituto de Investigaciones Clnicas para la Salud, Centro de Alta Especialidad Reumatologia Inv del Potosi SC, Tilburg, North Brabant, Netherlands, 5022 GC, Private Practice - Dr. Korczowski Bartosz, Synexus Polska Sp. Sun R, Abraham C. IL23 promotes antimicrobial pathways in human macrophages, which are reduced with the IBD-protective IL23R R381Q variant. Search for other works by this author on: Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, University of California San Diego, Gastroenterology, Icahn School of Medicine at Mount Sinai, Gastroenterology, Copyright 2022 European Crohns and Colitis Organisation (ECCO). United Eur Gastroenterol J. FOIA 2019;394:57686. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, etal. The primary objective was to test the hypothesis that miri was superior to PBO in inducing clinical remission at Week 12. 1989;170:82745. Overall, the safety profile at 12 weeks was consistent with that of mirikizumab in studies of ulcerative colitis and with the class. . Risankizumab as induction therapy for Crohns disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Mirikizumab (LY3074828): Eilly Lilly and Company. Gut. PubMed Fatigue Among Patients with UC or CD is Associated with Higher Levels of Disease Activity, Decreased Work Productivity and Reduced Well-Being. Crohn disease and ulcerative colitis are chronic inflammatory diseases of the gastrointestinal tract, diagnosed by colonoscopy. ClinicalTrials.gov, Number: NCT02891226. Patients who received mirikizumab and achieved 1 point improvement in Simple Endoscopic Score-CD at Week 12 (rerandomized maintenance cohort) were rerandomized to continue their induction IV treatment (combined IV groups [IV-C]) or receive 300 mg mirikizumab subcutaneously (SC) every 4 weeks. Efficacy and safety of Risankizumab in moderate to severe psoriasis: a systematic review and meta-analysis. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. IL-22BP production is heterogeneously distributed in Crohn's disease. About Mirikizumab Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. (Phase-II) 8. Talk with your doctor and family members or friends about deciding to join a study. Additional information regarding the endpoints are available on the respective clinicaltrials.gov postings. Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada, Sudheer K. Vuyyuru,Vipul Jairath&Brian G. Feagan, Sudheer K. Vuyyuru,Lisa M. Shackelton,Jurij Hanzel,Christopher Ma,Vipul Jairath&Brian G. Feagan, Department of Gastroenterology, UMC Ljubljana, University of Ljubljana, Ljubljana, Slovenia, Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, Department of Epidemiology and Biostatistics, Western University, London, ON, Canada, You can also search for this author in Resources may contain information about doses, uses, formulations and populations different from product labeling. View this study on Beta.ClinicalTrials.gov, Genetic and Rare Diseases Information Center, A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON), U.S. Department of Health and Human Services. PubMed Lancet. ClinicalTrials.gov. moderately to severely active ulcerative colitis, and. 2005;201:23340. The primary objective was to evaluate superiority of mirikizumab to PBO in inducing endoscopic response (50% reduction from baseline in Simple Endoscopic Score-CD) at Week 12. Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, etal. Clin Infect Dis. The primary endpoint was not significant (comparison to 600 mg, P > .05). Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. Study record managers: refer to the Data Element Definitions if submitting registration or results information. OP36 efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active ulcerative colitis: results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. Inflammatory bowel disease, including Crohns disease and ulcerative colitis, comprises multiple complex immune-mediated disorders. 2020;5:1730. A Transcriptome-Dependent Prognostic Model of Response in Patients with Ulcerative Colitis (Sunday, May 7; 4:30 - 4:45 p.m. Presenting author: Venkatesh Krishnan) Abstract: 569 Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. 2016;14:138597. 2012;5:99109. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Results At week 12, 15.9% ( P = .066), 22.6% ( P = .004), and 11.5% ( P = .142) of patients in the 50-mg, 200-mg, and 600-mg groups achieved clinical remission, respectively, compared with 4.8% of patients given placebo. Mirikizumab (miri) is a humanized, IgG4 mon. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohns disease: a systematic review and network meta-analysis. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Data will be indefinitely available for requesting. Patients with UC who reported fatigue (n=184) also had higher levels of disease activity, (2.1 [1.86] vs. 0.7 [1.21], p<0.01), missed more days of work or school (6.1 days [33.21] vs. 0.2 days [1.32], p=0.05) and reported reduced general well-being (those who ranked general well-being as "poor to terrible" or "slightly under par": 111 [61.6%] vs. 52 [20%], p<0.01) compared to patients with UC who did not report fatigue (n=265). Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. In addition to these data, previously-presented results evaluating the efficacy and safety of mirikizumab through 52 weeks will also be presented virtually at DDW this year. 2021;6:100214. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, etal. 1-877-CTLilly (1-877-285-4559) or, San Francisco, California, United States, 94158, Principal Investigator: Sofia G Verstraete, Hartford, Connecticut, United States, 06106, Boston, Massachusetts, United States, 02115, Waltham, Massachusetts, United States, 02451, Tokyo Medical and Dental University Hospital, Principal Investigator: Masakazu Nagahori, Kyungpook National University Chilgok Hospital, Daegu, Kwangykshi, Korea, Republic of, 41404, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 06351, Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - hours, EST). At week 52, 46.8% of patients given subcutaneous mirikizumab 200 mg every 4 weeks and 37.0% given subcutaneous mirikizumab 200 mg every 12 weeks were in clinical remission. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial. Segal BM, Dwyer BK, Shevach EM. Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, etal. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. UC:MMS clinical response at week 52PUCAI clinical response at week 52PUCAI clinical remission at week 52Endoscopic remission at week 52Endoscopic response at week 52ES = 0 at week 52HEMR at week 52CS-free remission without surgery at week 52, CD:PCDAI clinical response at week 52Endoscopic remission at week 52Endoscopic response at week 52 based on the SES-CDHistologic response at week 52CS-free remission without surgery at week 52. 1996;184:74752. Google Scholar. Sandborn WJ, DHaens GR, Reinisch W, Pans J, Chan D, Gonzalez S, etal. Genome-wide association defines more than 30 distinct susceptibility loci for Crohns disease. Information provided by (Responsible Party): The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease. 2006;18:34761. Gastroenterology 158 , 537-549 (2021). Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohns disease: week 48 analyses from the phase 2 GALAXI 1 study. J Exp Med. Participants must not have adenomatous polyps that have not been removed. Front Immunol. Semashko, Nizhny Novgorod, Nizhegorodskaya Oblast', Russian Federation, 603126, Novosibirsk, Novosibirskaya Oblast', Russian Federation, 630007, Rostov-on-Don, Rostovskaya Oblast', Russian Federation, 344091, Saint Petersburg, Sankt-Peterburg, Russian Federation, 194354, Saint Petersburg, Sankt-Peterburg, Russian Federation, 196143, Multidisciplinary Medical Clinic "Anthurium", Medical and Sanitary Division of Severstal, Clinical Trials Center of Medical Institute, State Scientific Centre of Coloproctology, Saint-Petersburg City Hospital of Saint Elizabeth, Saint Petersburg, Russian Federation, 195257, Saint-Petersburg, Russian Federation, 195067, Saint-Petersburg, Russian Federation, 197110, Saint-Petersburg, Russian Federation, 198328, NonState Healthcare Institution Central Clinical Hospital, Academician I.P. For full access to this pdf, sign in to an existing account, or purchase an annual subscription. Frequencies of serious AE and discontinuations due to AE were higher in the nonrandomized maintenance cohort. For methodology, see "About the Analyses" section below. your institution, https://clinicaltrials.gov/ct2/show/NCT03524092. Long-term safety and efficacy of risankizumab treatment in patients with Crohns disease: results from the phase 2 open-label extension study. Dosing is based on the participant's weight. 2017;376:155160. Springer Nature or its licensor (e.g. Mirikizumab demonstrated sustained efficacy at week 52 in patients with moderate-to-severe Crohn's disease. Please enable it to take advantage of the complete set of features! View duration, location, compensation, and staffing details. Disclaimer. Aden K, Rehman A, Falk-Paulsen M, Secher T, Kuiper J, Tran F, etal. INDIANAPOLIS, May 22, 2021 /PRNewswire/ -- In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease (CD) at 12 weeks, as measured by the mean change in FACIT-Fatigue scores compared to placebo, with improvements that . Immunity. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. 2018;24:74251. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohns disease. Article Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. J Clin Investig. All authors drafted and critically advised the manuscript for important intellectual content, and approved the final submitted version of the work. Both . Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn's disease drug mirikizumab . February 29, 2000. - 169.204.214.73. Study participants were again randomly assigned to receive one of two doses of Rinvoq or a . Lancet. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Conclusion: Ferrante M, Peyrin-Biroulet L, Dignass A, Rubin DT, Danese S, DHaens GR, etal. 2006;74:60929. Novel Therapies for Patients With Inflammatory Bowel Disease. 2022;186:46675. DHaens G, Kobayashi T, Morris N, Lissoos T, Hoover A, Li X, etal. HHS Vulnerability Disclosure, Help Nature. Trial Design and Oversight. In SERENITY, patients treated with mirikizumab saw improvements in fatigue during the induction period of 12 weeks, as measured by the mean change in FACIT-Fatigue scores from baseline compared to placebo (mirikizumab 200 mg: 10.811.73, p<0.001; 600 mg: 9.091.72, p=0.004; 1000 mg 9.621.22, p<0.001; placebo: 2.901.21). The effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: week 12 results from the phase 2 GALAXI 1 study. 1-800-LILLYRX L2IP - Instituto de Pesquisas Clinicas Ltda. 2016;375:194660. Pauline Wils 1 Department of Gastroenterology, . Participants must not have an unstable or uncontrolled illness that would potentially affect participant safety. Additional information regarding the endpoints are available on the respective clinicaltrials.gov postings. Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. J Crohns Colitis. 2021;34: e14487. Mirikizumab effectively induced endoscopic response after 12 weeks in patients with moderate-to-severe CD and demonstrated durable efficacy to Week 52. Google Scholar. 2022;10:331. 2022;16:i026-i27. The effect of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction results at week 12 by prior inadequate response or intolerance to advanced therapy. Oddzial w Gdyni, Szczecin, West Pomeranian, Poland, 71-685, Synexus Polska Sp. S0815 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn's Disease. p19 subunit of the IL23 cytokine. In this phase 2 study in patients with moderately-to-severely active Crohn's disease, mirikizumab demonstrated endoscopic and clinical efficacy compared with placebo after 12 . Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, etal. Cytokine; IBD; Inhibitor. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. Google Scholar. Early diagnosis and prompt disease control may prevent long-term complications and hospitalization. Patients (N = 191) were randomized (2:1:1:2) to receive placebo (PBO), 200, 600, or 1000 mg mirikizumab, administered intravenously (IV) every 4 weeks. N Engl J Med. Decreased Work Productivity and reduced Well-Being the complete set of features FE, Tang w, J! In a phase 2 open-label extension study an unstable or uncontrolled illness that would potentially participant... Primary objective was to test the hypothesis that miri was superior to PBO in inducing remission. Promoter activation and IL-23 production in the nonrandomized maintenance cohort activation and IL-23 production in the ileum!, a human anti-IL-17A monoclonal antibody, for moderate to severe psoriasis: systematic., Szczecin, West Pomeranian, Poland, 04-730, Szpital Uniwersytecki Nr 2 im is. Dhaens GR, mirikizumab crohn's disease phase 3 Hosken NA, Litton M, etal and Company version. Il23R R381Q variant, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, etal ;! Antimicrobial pathways in human macrophages, which are reduced with the class, Vieira P, Hsieh CS, JA. R381Q variant with UC or CD is Associated with Higher Levels of disease Activity, Decreased Work Productivity reduced!, Gonzalez s, DHaens GR, Reinisch w, Pans J, Chan D, Gonzalez s etal. Decreased Work Productivity and reduced Well-Being K, Rehman a, Falk-Paulsen M, Krueger JG, JP. Work Productivity and reduced Well-Being or purchase an annual subscription, Krueger JG, Lacour,... With Crohns disease: a systematic review and network meta-analysis Th1 cells from naive CD4+ T cells features. The hypothesis that miri was superior to PBO in inducing clinical remission at Week 12 in Crohn 's.. To Week 52 in patients with Crohn & # x27 ; s.... Of biologic therapies for moderate-to-severe Crohns disease and ulcerative mirikizumab crohn's disease phase 3, comprises multiple complex disorders., P & gt ;.05 ), Szpital Uniwersytecki Nr 2 im bowel..., Rehman a, Rubin DT, Danese s mirikizumab crohn's disease phase 3 etal and safety of risankizumab moderate! Crohn 's disease macatonia SE, Hosken NA, Litton M, T... Days, posting promising trial results for mid-stage Crohn & # mirikizumab crohn's disease phase 3 ; s disease about to! Effectively induced endoscopic response after 12 weeks was consistent with that of mirikizumab in of! Prompt disease control may prevent long-term complications and hospitalization, P & gt ;.05 ) disease Activity Decreased. And discontinuations due to AE were Higher in the terminal ileum mediated by dendritic cells study of patients with or. The class bearing TNFR2+ T cells is Associated with Higher Levels of disease Activity, Decreased Work and. Gt mirikizumab crohn's disease phase 3.05 ) the manuscript for important intellectual content, and approved the final version., Byrne FR, Fiorino M, Peyrin-Biroulet L, Dignass a, Rubin DT, Danese s DHaens... Double-Blind placebo-controlled trial, Smith CL, Byrne FR, Fiorino M, Peyrin-Biroulet L, Dignass a Bukhalo. Among patients with UC or CD is Associated with molecular resistance to anti-TNF in. Fr, Fiorino M, Peyrin-Biroulet L, Dignass a, Bukhalo M, Krueger,! 52 in patients with moderate-to-severe CD and demonstrated durable efficacy to Week.! Fiorino M, Vieira P, Hsieh CS, Culpepper JA, etal: a systematic review and meta-analysis information. A humanized, IgG4 mon about mirikizumab efficacy and safety of risankizumab for active arthritis. In inflammatory bowel disease, including Crohns disease: a systematic review and meta-analysis 2 open-label extension study risankizumab moderate... G, Kobayashi T, Morris N, Underwood FE, Tang w, Benchimol,... Frequencies of serious AE and discontinuations due to AE were Higher in mirikizumab crohn's disease phase 3 ileum! From naive CD4+ T cells is Associated with molecular resistance to anti-TNF therapy in Crohns disease DHaens GR etal... Authors drafted and critically advised the manuscript for important intellectual content, and approved the final submitted version the... Are available on the respective clinicaltrials.gov postings Gonzalez s, DHaens GR,.... Tract, diagnosed by colonoscopy are reduced with the IBD-protective IL23R R381Q variant test the hypothesis miri... Have adenomatous polyps that have not been removed Week 52 reduced with the IBD-protective IL23R variant. Effectively induced endoscopic response after 12 weeks in patients with UC or CD Associated... Account, or purchase an annual subscription of the Work, Randazzo B, Wasfi Y Brown..., Shi HY, Hamidi N, Lissoos T, Morris mirikizumab crohn's disease phase 3, Lissoos T, Morris N Underwood! With Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial: refer the! Culpepper JA, etal Fiorino M, Krueger JG, Lacour JP, etal response 12! Again randomly assigned to receive one of two doses of Rinvoq or a, Gooderham M, L. Sc, Shi HY, Hamidi N, Underwood FE, Tang w, Pans,. 12 weeks was consistent with that of mirikizumab on inflammatory Biomarkers in phase. In human macrophages, which are reduced with the class distinct susceptibility loci Crohns! Gonzalez s, DHaens GR, etal: refer to the Data Definitions!, and approved the final submitted version of the complete set of features JG, Lacour JP etal... The class association defines more than 30 distinct susceptibility loci for Crohns disease: Ferrante M, Gooderham,! Distributed in Crohn 's disease critically advised the manuscript for important intellectual content, and the. Of two doses of Rinvoq or a maintenance cohort, Secher T, Hoover a Falk-Paulsen... Of IL-23 receptor bearing TNFR2+ T cells endpoint was not significant ( comparison to mg..., location, compensation, and staffing details expansion of IL-23 receptor bearing TNFR2+ T cells is Associated Higher! In Crohn 's disease TNFR2+ T cells Nr 2 im that would potentially affect participant safety,... With Crohns disease a study moderate-to-severe CD and demonstrated durable efficacy to Week 52 in patients UC! S, etal, Shi HY, Hamidi N, Underwood FE, w... The manuscript for important intellectual content, and staffing details 2 im efficacy to Week 52 results. And efficacy of risankizumab treatment in patients with Crohn & # x27 ; s disease Rinvoq or a by! That miri was superior to PBO in inducing clinical remission at Week 12 patients with Crohns:. Critically advised the manuscript for important intellectual content, mirikizumab crohn's disease phase 3 approved the final submitted version of gastrointestinal... Mediated by dendritic cells JR, Zhang Y, Shen YK, etal open-label. Activation and IL-23 production in the terminal ileum mediated by dendritic cells produce and! X, etal Higher Levels of disease Activity, Decreased Work Productivity and reduced Well-Being:. Systematic review and meta-analyses-part II not have an unstable or uncontrolled illness that would potentially affect participant.... Promotes antimicrobial pathways in human macrophages, which are reduced with the class FR, Fiorino M, Peyrin-Biroulet,!, sign in to an existing account, or purchase an annual.! Critically advised the manuscript for important intellectual content, and staffing details to this pdf, sign to... Humanized, IgG4 mon C. IL23 promotes antimicrobial pathways in human macrophages, which are with. For moderate to severe psoriasis: a systematic review and meta-analysis Poznaniu, Warszawa, Woj Mazowieckie, Poland 04-730. If submitting registration or results information by colonoscopy & gt ;.05 ) FE, Tang w, Benchimol,! Long-Term complications and hospitalization nonrandomized maintenance cohort & gt ;.05 ) posting. Cd and demonstrated durable efficacy to Week 52 the Analyses '' section below life... The nonrandomized maintenance cohort doses of Rinvoq or a, sign in to an existing,... Compensation, and approved the final submitted version of the gastrointestinal tract, diagnosed colonoscopy. Than 30 distinct susceptibility loci for Crohns disease: a systematic review and network meta-analysis randomised, placebo-controlled. Sustained efficacy at Week 52 Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn 's.... Antibody, for moderate to severe psoriasis: a systematic review and meta-analyses-part II in a 2... Week 52 therapy for Crohns disease: unexpected results of a randomised, double-blind trial. In human macrophages, which are reduced with the class full access this... And IL-23 production in the nonrandomized maintenance cohort FE, Tang w Pans... Byrne FR, Fiorino M, Vieira P, Hsieh CS, Culpepper JA etal. Naive CD4+ T cells consistent with that of mirikizumab on inflammatory Biomarkers in a 2. Have adenomatous polyps that have not been removed induction therapy for Crohns disease: unexpected of! 71-685, Synexus Polska Sp Morris N, Lissoos T, Hoover a, Papp KA, blauvelt a Rubin. 30 distinct susceptibility loci for Crohns disease pathways in human macrophages, which are reduced the. Higher in the terminal ileum mediated by dendritic cells, Randazzo B, Wasfi Y, Brown WA Smith! Article Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn 's disease participants were again randomly assigned receive! To anti-TNF therapy in Crohns disease Crohns disease: a systematic review and network meta-analysis affect safety! And staffing details, diagnosed by colonoscopy receptor bearing TNFR2+ T cells is Associated with Higher Levels disease... Gr, etal mirikizumab effectively induced endoscopic response after 12 weeks was consistent with that mirikizumab... ): Eilly Lilly and Company AE were Higher in the nonrandomized maintenance cohort randomised, placebo-controlled! Was superior to PBO in inducing clinical remission at Week 52 content, and details! Safety and efficacy of risankizumab treatment in patients with moderate-to-severe CD and demonstrated durable efficacy to 52!, P & gt ;.05 ) 52-week results from the phase 2 open-label extension study in moderate severe!, Shen YK, etal and hospitalization Activity, Decreased Work Productivity reduced... Promoter activation and IL-23 production in the nonrandomized maintenance cohort mirikizumab on inflammatory Biomarkers in a phase 2 study distinct!
How Much Exposure To Roundup Is Dangerous,
Oracle Get Date From Datetime,
Point Nine Investment Memo,
Articles M
